Research Progress of Sodium-glucose Cotransporter 2 Inhibitor in the Treatment of T2DM Complicated with Coronary Heart Disease

doi:10.12114/j.issn.1007-9572.2022.02.024

Abstract

Abstract:

Diabetes is an independent risk factor for coronary heart disease, and the two are mutually causal in disease progression. Sodium-glucose cotransporter 2 inhibitor is a new oral medicine for the treatment of type 2 diabetes mellitus, which can play a hypoglycemic effect by blocking the reabsorption of glucose by the renal proximal convoluted tubules and increasing the excretion of urine glucose. A large number of studies have confirmed that in addition to hypoglycemic effects, SGLT2 inhibitors can also benefit in the treatment of coronary heart disease. This article mainly reviews the research progress and mechanism of SGLT2 inhibitors in the treatment of T2DM complicated with coronary heart disease.

Key words: Diabetes mellitus, type 2, Coronary disease, Sodium-glucose transporter 2 inhibitors, Therapy, Review

摘要：

糖尿病是冠心病的独立危险因素，两者在疾病进展中互为因果。钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是治疗2型糖尿病（T2DM）的新型口服药物，通过阻断肾近曲小管对葡萄糖的重吸收进而增加尿葡萄糖排泄，从而发挥降糖作用。已有大量研究证实SGLT2抑制剂除发挥降糖作用外，还可在冠心病治疗中获益。本文主要对SGLT2抑制剂治疗T2DM合并冠心病的研究进展及作用机制作一综述。

关键词: 糖尿病，2型, 冠心病, 钠-葡萄糖共转运蛋白2抑制剂, 治疗, 综述

Zikang FU,Haiying LI,Ping LI. Research Progress of Sodium-glucose Cotransporter 2 Inhibitor in the Treatment of T2DM Complicated with Coronary Heart Disease[J]. Chinese General Practice, 2022, 25(12): 1493-1499. DOI: 10.12114/j.issn.1007-9572.2022.02.024.
付子康,李海英,李屏. 钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并冠心病的研究进展[J]. 中国全科医学, 2022, 25(12): 1493-1499. DOI: 10.12114/j.issn.1007-9572.2022.02.024.

References 59

[1]	高中山，任明，刘杏利，等. 短链脂肪酸在冠心病防治中的研究进展[J]. 临床心血管病杂志，2021，37(11)：1062-1066. DOI：10.13201/j.issn.1001-1439.2021.11.019.
[2]	辛琦，孙洪涛. 冠心病合并糖尿病临床治疗的研究进展[J]. 中西医结合心血管病杂志，2018，6(12)：12-17. DOI：10.16282/j.cnki.cn11-9336/r.2018.12.010.
[3]	NORHAMMAR A, MALMBERG K, DIDERHOLM E，et al. Diabetes mellitus：the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization[J]. J Am Coll Cardiol，2004，43(4)：585-591. DOI：10.1016/j.jacc.2003.08.050.
[4]	HAMMOUD T, TANGUAY J F, BOURASSA M G. Management of coronary artery disease：therapeutic options in patients with diabetes[J]. J Am Coll Cardiol，2000，36(2)：355-365. DOI：10.1016/s0735-1097(00)00732-4.
[5]	LAHNWONG S, PALEE S, APAIJAI N，et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury[J]. Cardiovasc Diabetol，2020，19(1)：91. DOI：10.1186/s12933-020-01066-9.
[6]	KATO E T, SILVERMAN M G, MOSENZON O，et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J]. Circulation，2019，139(22)：2528-2536. DOI：10.1161/CIRCULATIONAHA.119.040130.
[7]	MCDONALD M, VIRANI S, CHAN M，et al. CCS/CHFS heart failure guidelines update：defining a new pharmacologic standard of care for heart failure with reduced ejection fraction[J]. Can J Cardiol，2021，37(4)：531-546. DOI：10.1016/j.cjca.2021.01.017.
[8]	王亚东，杨延泽，魏金娜，等. SGLT2抑制剂治疗糖尿病心血管并发症的机制研究进展[J]. 江苏大学学报：医学版，2021，31 (4)：356-362. DOI：10.13312/j.issn.1671-7783.y200222.
[9]	欧昌元. 糖尿病合并冠心病的影像学研究进展[J]. 医学综述，2011，17(2)：290-292. DOI：10.3969/j.issn.1006-2084.2011.02.046.
[10]	WILCOX T, DE BLOCK C, SCHWARTZBARD A Z，et al. Diabetic agents，from metformin to SGLT2 inhibitors and GLP1 receptor agonists：JACC focus seminar[J]. J Am Coll Cardiol，2020，75(16)：1956-1974. DOI：10.1016/j.jacc.2020.02.056.
[11]	苏工，高明喜，杨红霞. 2020年美国心脏病学会《降低2型糖尿病患者心血管风险新型疗法的专家共识决策路径》解读：降糖更要护心[J]. 中国全科医学，2021，24(5)：509-516. DOI：10.12114/j.issn.1007-9572.2021.00.111.
[12]	宋莉平. HbA1c、Hcy与T2DM合并冠心病患者冠状动脉狭窄程度的相关性[J]. 西藏医药，2021，42(2)：26-28.
[13]	KITADA M, ZHANG Z Y, MIMA A，et al. Molecular mechanisms of diabetic vascular complications[J]. J Diabetes Investig，2010，1(3)：77-89. DOI：10.1111/j.2040-1124.2010.00018.x.
[14]	ERGUL A. Endothelin-1 and diabetic complications：focus on the vasculature[J]. Pharmacol Res，2011，63(6)：477-482. DOI：10.1016/j.phrs.2011.01.012.
[15]	FADINI G P, SARTORE S, AGOSTINI C，et al. Significance of endothelial progenitor cells in subjects with diabetes[J]. Diabetes Care，2007，30(5)：1305-1313. DOI：10.2337/dc06-2305.
[16]	ONG P, CAMICI P G, BELTRAME J F，et al. International standardization of diagnostic criteria for microvascular angina[J]. Int J Cardiol，2018，250：16-20. DOI：10.1016/j.ijcard.2017.08.068.
[17]	CREAGER M A, LÜSCHER T F, COSENTINO F，et al. Diabetes and vascular disease：pathophysiology，clinical consequences，and medical therapy：part I[J]. Circulation，2003，108(12)：1527-1532. DOI：10.1161/01.CIR.0000091257.27563.32.
[18]	COSENTINO F, GRANT P J, ABOYANS V，et al. 2019 ESC Guidelines on diabetes，pre-diabetes，and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J，2020，41(2)：255-323. DOI：10.1093/eurheartj/ehz486.
[19]	BENJAMIN E J, MUNTNER P, ALONSO A，et al. Heart disease and stroke statistics——2019 update：a report from the American heart association[J]. Circulation，2019，139(10)：e56-528. DOI：10.1161/CIR.0000000000000659.
[20]	许猛. 糖化血红蛋白、血脂及尿酸在2型糖尿病合并冠心病患者的检测意义[J]. 现代诊断与治疗，2021，32(18)：2963-2964.
[21]	SANO R, SHINOZAKI Y, OHTA T. Sodium-glucose cotransporters：functional properties and pharmaceutical potential[J]. J Diabetes Investig，2020，11(4)：770-782. DOI：10.1111/jdi.13255.
[22]	秦伟彬，何贵新，林琳，等. 不同尿酸水平老年冠心病患者血管内超声检查结果比较研究[J]. 中国全科医学，2020，23(6)：656-661. DOI：10.12114/j.issn.1007-9572.2019.00.755.
[23]	吕赛，周玉杰，刘巍. 高尿酸血症、代谢综合征与冠心病的研究进展[J]. 心肺血管病杂志，2018，37(1)：76-78. DOI：10.3969/j.issn.1007-5062.2018.01.019.
[24]	朱政斌，沈卫峰. 肾功能不全冠心病患者危险因素控制及药物治疗进展[J]. 国际心血管病杂志，2007，34(6)：398-401. DOI：10.3969/j.issn.1673-6583.2007.06.003.
[25]	MCMURRAY J J V, SOLOMON S D, INZUCCHI S E，et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med，2019，381(21)：1995-2008. DOI：10.1056/NEJMoa1911303.
[26]	GIUGLIANO D, MAIORINO M I, BELLASTELLA G，et al. Glycemic control，preexisting cardiovascular disease，and risk of major cardiovascular events in patients with type 2 diabetes mellitus：systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials[J]. J Am Heart Assoc，2019，8(12)：e012356. DOI：10.1161/JAHA.119.012356.
[27]	李鑫，李焕德. 一类全新机制的2型糖尿病治疗药物SGLT2抑制剂[J]. 中南药学，2018，16(3)：289-296.
[28]	ZINMAN B, WANNER C, LACHIN J M，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J]. N Engl J Med，2015，373(22)：2117-2128. DOI：10.1056/NEJMoa1504720.
[29]	NEAL B, PERKOVIC V, MAHAFFEY K W，et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med，2017，377(7)：644-657. DOI：10.1056/NEJMoa1611925.
[30]	WIVIOTT S D, RAZ I, BONACA M P，et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med，2019，380(4)：347-357. DOI：10.1056/NEJMoa1812389.
[31]	PERKOVIC V, JARDINE M J, NEAL B，et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med，2019，380(24)：2295-2306. DOI：10.1056/NEJMoa1811744.
[32]	FURTADO R H M, BONACA M P, RAZ I，et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction[J]. Circulation，2019，139 (22)：2516-2527. DOI：10.1161/CIRCULATIONAHA.119.039996.
[33]	KOSIBOROD M, CAVENDER M A, FU A Z，et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs：the CVD-REAL study （comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors）[J]. Circulation，2017，136(3)：249-259. DOI：10.1161/CIRCULATIONAHA.117.029190.
[34]	KOSIBOROD M, LAM C S P, KOHSAKA S，et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs：the CVD-REAL 2 study[J]. J Am Coll Cardiol，2018，71(23)：2628-2639. DOI：10.1016/j.jacc.2018.03.009.
[35]	QUAN N H, LI X, ZHANG J W，et al. Substrate metabolism regulated by Sestrin2-mTORC1 alleviates pressure overload-induced cardiac hypertrophy in aged heart[J]. Redox Biol，2020，36：101637. DOI：10.1016/j.redox.2020.101637.
[36]	JAIKUMKAO K, PROMSAN S, THONGNAK L，et al. Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats[J]. J Cell Physiol，2021，236(9)：6424-6440. DOI：10.1002/jcp.30316.
[37]	FERRANNINI E, MARK M, MAYOUX E. CV protection in the EMPA-REG OUTCOME trial：a "thrifty substrate" hypothesis[J]. Diabetes Care，2016，39(7)：1108-1114. DOI：10.2337/dc16-0330.
[38]	SANTOS-GALLEGO C G, IBANEZ J A R, ANTONIO R S，et al. Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility[J]. J Am Coll Cardiol，2018，71(11)：A674. DOI：10.1016/S0735-1097(18)31215-4.
[39]	SANTOS-GALLEGO C G, REQUENA-IBANEZ J A, SAN ANTONIO R，et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics[J]. J Am Coll Cardiol，2019，73(15)：1931-1944. DOI：10.1016/j.jacc.2019.01.056.
[40]	梁志山，许志盟，吉庆伟. 钠-葡萄糖共转运蛋白2抑制剂治疗心力衰竭循证证据与机制的研究进展[J]. 中国临床新医学，2021，14(6)：554-558. DOI：10.3969/j.issn.1674-3806.2021.06.06.
[41]	高文君，韩明华. 急性冠脉综合征预后的预测研究进展[J]. 心血管病学进展，2018，39(4)：606-610. DOI：10.16806/j.cnki.issn.1004-3934.2018.04.025.
[42]	王继航，沈明志，焦阳，等. SGLT2i在合并糖尿病动脉粥样硬化性心血管疾病中的作用研究进展[J]. 中华老年多器官疾病杂志，2021，20(4)：300-304. DOI：10.11915/j.issn.1671-5403.2021.04.062.
[43]	KANG S A, VERMA S, HASSANABAD A F，et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts：novel translational clues to explain EMPA-REG OUTCOME results[J]. Can J Cardiol，2020，36(4)：543-553. DOI：10.1016/j.cjca.2019.08.033.
[44]	LEE T M, CHANG N C, LIN S Z. Dapagliflozin，a selective SGLT2 Inhibitor，attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts[J]. Free Radic Biol Med，2017，104：298-310. DOI：10.1016/j.freeradbiomed.2017.01.035.
[45]	YE Y M, JIA X M, BAJAJ M，et al. Dapagliflozin attenuates Na⁺/H⁺ exchanger-1 in cardiofibroblasts via AMPK activation[J]. Cardiovasc Drugs Ther，2018，32(6)：553-558. DOI：10.1007/s10557-018-6837-3.
[46]	BAARTSCHEER A, SCHUMACHER C A, WÜST R C，et al. Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits[J]. Diabetologia，2017，60(3)：568-573. DOI：10.1007/s00125-016-4134-x.
[47]	UTHMAN L, BAARTSCHEER A, BLEIJLEVENS B，et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts：inhibition of Na⁺/H⁺ exchanger，lowering of cytosolic Na⁺ and vasodilation[J]. Diabetologia，2018，61(3)：722-726. DOI：10.1007/s00125-017-4509-7.
[48]	ZHOU H, HU S Y, JIN Q H，et al. Mff-dependent mitochondrial fission contributes to the pathogenesis of cardiac microvasculature ischemia/reperfusion injury via induction of mROS-mediated cardiolipin oxidation and HK2/VDAC1 disassociation-involved mPTP opening[J]. J Am Heart Assoc，2017，6(3)：e005328. DOI：10.1161/JAHA.116.005328.
[49]	SAWADA N, JIANG A H, TAKIZAWA F，et al. Endothelial PGC-1α mediates vascular dysfunction in diabetes[J]. Cell Metab，2014，19(2)：246-258. DOI：10.1016/j.cmet.2013.12.014.
[50]	ZHOU H, WANG S Y, ZHU P J，et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission[J]. Redox Biol，2018，15：335-346. DOI：10.1016/j.redox.2017.12.019.
[51]	HANSSON G K, LIBBY P. The immune response in atherosclerosis：a double-edged sword[J]. Nat Rev Immunol，2006，6(7)：508-519. DOI：10.1038/nri1882.
[52]	NASIRI-ANSARI Ν, DIMITRIADIS G K, AGROGIANNIS G，et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice[J]. Cardiovasc Diabetol，2018，17(1)：106. DOI：10.1186/s12933-018-0749-1.
[53]	MANCINI S J, BOYD D, KATWAN O J，et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and-independent mechanisms[J]. Sci Rep，2018，8(1)：5276. DOI：10.1038/s41598-018-23420-4.
[54]	NAKATSU Y, KOKUBO H, BUMDELGER B，et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice[J]. Int J Mol Sci，2017，18(8)：1704. DOI：10.3390/ijms18081704.
[55]	LENG W L, OUYANG X S, LEI X T，et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/- mice[J]. Mediators Inflamm，2016，2016：6305735. DOI：10.1155/2016/6305735.
[56]	白书会，梁江久. 心率变异性与冠心病相关性研究进展[J]. 实用临床医学，2020，21(4)：88-92. DOI：10.13764/j.cnki.lcsy.2020.04.029.
[57]	SCHEEN A J. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure[J]. Curr Cardiol Rep，2019，21(8)：70. DOI：10.1007/s11886-019-1165-1.
[58]	ZHANG N N, FENG B, MA X X，et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol，2019，18(1)：107. DOI：10.1186/s12933-019-0914-1.
[59]	PACKER M. Molecular，cellular，and clinical evidence that sodium-glucose cotransporter 2 inhibitors act as neurohormonal antagonists when used for the treatment of chronic heart failure[J]. J Am Heart Assoc，2020，9(16)：e016270. DOI：10.1161/JAHA.120.016270.